1Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, CA Cancer J Clin 69: 7–34.

2Recio-Boiles A, Waheed A, Cagir B (2019) Cancer, Colon. StatPearls [Internet] Treasure Island (FL): Stat Pearls Publishing.

3Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C (2019) High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci 20.

4Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177: 1053–1064.

5Fung-Kee-Fung M, Oliver T, Elit L, Oza A, et al. (2007) Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 14:195-208.

6Myers EA, Feingold DA, Forde KA, Arnell T, Jang JH, Whelan RL (2013) Colorectal cancer in patients under 50 years of age: A retrospective analysis of two institutions' experience. World J Gastroenterol 19: 5651–5657.

7Césaire M, Thariat J, Candéias SM, Stefan D, Saintigny Y, Chevalier F (2018) Combining PARP Inhibition, Radiation, and Immunotherapy: A possible strategy to improve the treatment of cancer? Int J Mol Sci 19.

8Luvero D, Milani A, Ledermann JA (2014) Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol 6: 229–239.

9Coward JI, Middleton K, Murphy F (2015) New perspectives on targeted therapy in ovarian cancer. Int J Women's Health 7: 189–203.

10Giordano G, Remo A, Porras A, Pancione M (2019) Immune resistance and EGFR antagonists in colorectal cancer. Cancers. Cancers (Basel) 11.

11Beloribi-Djefaflia S, Vasseur S, Guillaumond F (2016) Lipid metabolic reprogramming in cancer cells. Oncogenesis e189.

12Marinho AT, Lu H, Pereira SA, Monteiro E, Gabra H, Recchi C (2019) Anti-tumorigenic and platinum-sensitizing effects of apolipoprotein A1 and apolipoprotein A1 mimetic peptides in ovarian cancer. Front Pharmacol 9: 1524.

13White CR, Garber DW, Anantharamaiah GM (2014) Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review. J Lipid Res 55: 2007-20021.

14Navab M, Reddy ST, Van Lenten BJ, Buga GM, Hough G, Wagner AC, et al. (2012) High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of the literature. Arterioscler Thromb Vasc Biol 32: 2553–2560.

15Zamanian-Daryoush M, DiDonato JA (2015) Apolipoprotein A-I and cancer. Front Pharmacol 6: 265.

16Bauchart D (1993) Lipid adsorption and transport in ruminants. J. Dairy Sci 76: 3864-3881.

17Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalwa V, et al. (2010) Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc. Natl Acad Sci USA 107: 19997–20002.

18Gao F, Vasquez SX, Su F, Roberts S, Shah N, Grijalva V, et al. (2011) L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr Biol (Camb) 3: 479–489.

19Ganapathy E, Su F, Meriwether D, Devarajan A, Grijalva V, Gao F, et al. (2012) D-4F, an apoA-I mimetic peptide inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD. In J Cancer 130:1071–1081.

20Su F, Grijalva V, Navab K, Ganapathy E, Meriwether D, Imaizumi S, et al. (2012) HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther 11: 1311–1319.

21Gao F, Chattopadhyay A, Navab M, Grijalva V, Su F, Fogelman AM, et al. (2012) Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1α in human ovarian cancer cell lines and a mouse ovarian cancer model. J Pharmacol Exp Ther 342: 255-262.

22Gupta H, White CR, Handattu S, Garber DW, Datta G, Chaddha M, et al. (2005) Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in Watanabe heritable hyperlipidemic rabbits. Circulation 111: 3112-3118.

23Lowry OH, Rosbrough NJ, Farr AL, Randall RJ (1951)The Lowry method for protein quantification. J. Biol. Chem 193: 265-275.

24Handattu SP, Datta G, Epand RM, Epand RF, Palgunachari MN, Mishra VK, et al. (2010) Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice. J. Lipid. Res 51: 3491–3499.

25Anantharamaiah GM, Garber DW, Goldberg D, Morrel E, Datta G, Palgunachari MN, et al. (2018) Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaques. J Lipid Res 59: 2075-2083.

26Giordano-Mooga S, Datta G, Wolkowicz P, Garber DW, Palgunachari M, White CR, et al. (2018) Apolipoprotein E mimetic peptide AEM-2 attenuates mitochondrial injury and apoptosis in human THP-1 macrophages. Curr. Top Pept Protein Res 19:15-25.

27Shi H, Huang H, Pu J, Shi D, Ning Y, Dong Y, et al. (2018) Decreased pretherapy serum apolipoprotein A-I is associated with the extent of metastasis and poor prognosis of non-small-cell lung cancer. Onco Targets Ther. 11: 6995-7003.

28Namiri-Kalantari R, Feng G, Chattopadhyay A, Wheeler AA, Navab KD, Farias-Isner R, et al. (2015) The dual nature of HDL: Antiinflammatory and pro-inflammatory. Biofactors 41:153-159.

29Patel VK, Williams H, Li SCH, Fletcher JP, Medbury HJ (2017) Monocyte inflammatory profile is specific for individuals and associated with altered blood lipid levels. Atherosclerosis 263: 15-23.

30Tönnies E, Trushina E (2017) Oxidative stress, synaptic dysfunction, and Alzheimer's disease. J Alzheimers Dis 57: 1105-11021.

31Uehara Y, Chiesa G, Saku K (2015) High-Density Lipoprotein-targeted therapy and apolipoprotein A-I mimetic peptides. Circ J. 79: 2523-2528.

32Handattu SP, Nayyar G, Garber DW, Palgunachari MN, Monroe CE, Keenum TD, et al. (2013)Two apolipoprotein E mimetic peptides with similar cholesterol-reducing properties exhibit differential atheroprotective effects in LDL-R null mice. Atherosclerosis 227: 58-64.

33Guirgis FW, Leeuwenburgh C, Grijalva V, Bowman J, Kalynych C, Moldawer L, et al. (2018) HDL cholesterol efflux is impaired in older patients with early sepsis: a subanalysis of a prospective pilot study. Shock 50: 66 -70.

34Chen Y-C, Pohl G, Wang T-L, Morin PJ, Risberg B, Kristensen GB, et al. (2005) Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res 65: 331-337.

35Shi H, Huang H, Pu J, Shi D, Ning Y, Dong Y, et al. (2018) Decreased pretherapy serum apolipoprotein A-I is associated with the extent of metastasis and poor prognosis of non-small-cell lung cancer. Onco Targets Ther. 11: 6995–7003.

36Ifere GO, Desmond R, Wahnefried WD, Nagy TR (2013) Apolipoprotein E gene polymorphism influences aggressive behavior in prostate cancer cells by deregulating cholesterol homeostasis. Int J Oncol 43:1002-1010.

37Qi Y, Liu J, Wang W, Wang M, Zhao F, Sun J, et al. (2018) Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk: A community-based cohort study. J Clin Lipidol 12: 89-98.

38Hoter A, Naim HY (2019) Heat Shock Proteins and Ovarian Cancer: Important roles and therapeutic opportunities. Cancers 11: 1389-1408.

39Koltai T (2014) Clusterin: a key player in cancer chemoresistance and its inhibition. Onco Targets and Therapy 7: 447.

40Sansanwal P, Li L, Sarwal MM (2015) Inhibition of intracellular clusterin attenuates cell death in nephropathic cystinosis. J Amer Soc Nephrol 26: 612–625.

41Lin CC, Tsai P, Sun HY, Hsu MC, Lee JC, Wu IC, et al. (2014) Apolipoprotein J, a glucose-upregulated molecular chaperone, stabilizes core and NS5A to promote infectious hepatitis C virus virion production. J. Hepatol 61: 984–993.

42Jones SE, Jomary C. Clusterin (2002) International J Biochem Cell Biol 34: 427–431.

43Datta G, Garber DW, Chung BH, Chaddha M, Dashti N, Bradley WA, et al. (2001) Cationic domain 141- 150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. J. Lipid Res 42: 959-966.

44Nayyar G, Garber DW, Palgunachari MN, Monroe CE, Keenum TD, Handattu SP, et al. (2012) Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice. Atherosclerosis 224: 326-331.

45Garber DW, Goldberg D, Anantharamaiah GM (2015) Apolipoprotein mimetic peptides: cholesterol-dependent and cholesterol-independent properties. From the book "Effects of ApoA-I Mimetic Peptide L-4F in LPS-Mediated Inflammation (pp.135-156)".

46Samantha Giordano-Mooga, Geeta Datta, Paul Wolkowicz, David W. Garber, Mayakonda Palgunachari, C. Roger White, et al. The apoliporotein E mimetic peptide AEM-2 attenuates mitochondrial injury and apoptosis in human THP-1 macrophages. Curr Top Pept Protein Res. 2018; 19:15-25.

47Su F, Spee C, Araujo E, Barron E, Wang M, Ghione C, et al. (2019) A novel HDL-mimetic peptide HM-10/10 protects RPE and photoreceptors in murine models of retinal degeneration. Int J Mol Sci 20.

48Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, et al. (1998) Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280: 719–723.

49Westermann AM, Havik E, Postma FR, Beijnen JH, Dalesio O, Moolenaar WH, et al. (1998) Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 9: 437-442.